KALA News and Press, Kala Pharmaceuticals Inc. From 11/10/19

Kala Pharmaceuticals, Inc. (KALA) Q3 2019 Earnings Conference Call November 07, 2019 08:00 AM ET Company Participants Niranjan Kameswaran - Vice President, Strategy Mary Reumuth - Chief Financial Officer Mark Iwicki - Chairman, President & Chief Executive Officer Kim Brazze...

Kala Pharmaceuticals (NASDAQ: KALA ): Q3 GAAP EPS of -$0.68 misses by $0.04 . More news on: Kala Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

–Conference Call and Webcast Today at 8:00 a.m. ET– Kala Pharmaceuticals, Inc. (Kala) (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug D...

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today announced that it will report third quarter 2019 finan...

Quick Take Oyster Point Pharma ( OYST ) intends to raise $85 million in an IPO of its common stock, according to an S-1/A registration statement . The company is advancing drug treatments for certain eye conditions. OYST has a potential upside catalyst in mid-2020 and the IPO appears re...

Quick Take Oyster Point Pharma (OYST) has filed to raise gross proceeds of $85 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing treatments for ocular surface diseases. OYST has produced very promising results in Phase 2b trials for its lead ca...

Kala Pharmaceuticals ( KALA ) announced that the FDA had given it a complete response letter ((CRL)) for its dry eye disease treatment KPI-121 0.25%. While this was disappointing news for both the company and its investors, there is still another shot on goal. That is, it may be possible...

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today announced that members of its management team will par...

Healthcare research is laying the groundwork for drug technology that has never been seen before. By improving product efficacy and safety, as well as patient convenience and compliance, drugs are becoming more sophisticated with every passing year. Novel drug delivery technologies must overcom...

The U.S. is by far the global leader in healthcare research, and the reason is that the government promotes the research and development of innovative drugs and devices through reimbursements to the physicians who purchase them. It's this very important drug payback system that confers a huge ad...